A share price of Arcutis Biotherapeutics Inc [ARQT] is currently trading at $13.02, down -2.98%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ARQT shares have gain 5.77% over the last week, with a monthly amount drifted -5.03%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcutis Biotherapeutics Inc [NASDAQ: ARQT] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $19. Previously, Jefferies started tracking the stock with Buy rating on August 28, 2024, and set its price target to $15. On January 03, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $8 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on October 26, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $6 on October 13, 2023. Needham started tracking with a Buy rating for this stock on September 07, 2022, and assigned it a price target of $46. In a note dated March 17, 2022, Goldman initiated an Buy rating and provided a target price of $45 on this stock.
Arcutis Biotherapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.99 and $16.20. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Arcutis Biotherapeutics Inc [NASDAQ: ARQT] shares were valued at $13.02 at the most recent close of the market. An investor can expect a potential return of 45.93% based on the average ARQT price forecast.
Analyzing the ARQT fundamentals
Trailing Twelve Months sales for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] were 138.71M which represents 17.44% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.31%, Pretax Profit Margin comes in at -1.41%, and Net Profit Margin reading is -1.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -1.19 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.53 points at the first support level, and at 12.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.72, and for the 2nd resistance point, it is at 14.43.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Arcutis Biotherapeutics Inc [NASDAQ:ARQT] is 2.46. In addition, the Quick Ratio stands at 2.38 and the Cash Ratio stands at 0.78. Considering the valuation of this stock, the price to sales ratio is 10.99, the price to book ratio is 9.72.
Transactions by insiders
Recent insider trading involved Matsuda Masaru, that happened on Feb 03 ’25 when 8338.0 shares were sold. Watanabe Todd Franklin completed a deal on Feb 03 ’25 to sell 19301.0 shares. Meanwhile, Director Welgus Howard G. sold 10000.0 shares on Feb 03 ’25.
